Cocrystal Pharma (Nasdaq:COCP) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

COCP Panoramica delle azioni

Cocrystal Pharma, Inc. è una società di biotecnologie che si concentra sulla scoperta e sullo sviluppo di trattamenti terapeutici antivirali per malattie virali gravi e/o croniche.

Informazioni sull'azienda

COCP analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Gli utili sono cresciuti del 18.5% all'anno negli ultimi 5 anni

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 15.3% all'anno per i prossimi 3 anni

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Non ha una capitalizzazione di mercato significativa ( $19M )

+ 1 più rischio

Cocrystal Pharma, Inc. Concorrenti

Acasti Pharma

NasdaqCM:ACST

US$24.3m

VYNE Therapeutics

NasdaqCM:VYNE

US$27.7m

Cara Therapeutics

NasdaqCM:CARA

US$18.8m

Talphera

NasdaqGM:TLPH

US$15.3m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Cocrystal Pharma
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$1.98
Massimo di 52 settimane	US$3.24
Minimo di 52 settimane	US$1.33
Beta	1.41
1Variazione di 1 mese	-12.39%
Variazione a 3 mesi	-10.00%
Variazione di 1 anno	-30.77%
3Variazione a 3 anni	-85.78%
Variazione a 5 anni	-92.79%
Variazione dall'IPO	-99.19%

Notizie e aggiornamenti recenti

Recent updates

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Oct 11

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Aug 15

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Aug 14

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Aug 08

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Mar 19

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Nov 19

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Aug 06

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Jun 14

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

May 05

Cocrystal Pharma updates on COVID-19 antiviral development programs

May 03

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Mar 13

Rendimenti per gli azionisti

	COCP	US Pharmaceuticals	US Mercato
7D	8.8%	2.5%	1.6%
1Y	-30.8%	18.4%	26.4%

Ritorno vs Industria: COCP ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 16 % nell'ultimo anno.

Rendimento vs Mercato: COCP ha avuto una performance inferiore al mercato US che ha registrato un rendimento 25.6 % nell'ultimo anno.

Volatilità dei prezzi

Is COCP's price volatile compared to industry and market?
COCP volatility
COCP Average Weekly Movement	11.0%
Pharmaceuticals Industry Average Movement	10.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.2%

Prezzo delle azioni stabile: Il prezzo delle azioni di COCP è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 11% ) di COCP è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	12	Sam Lee	www.cocrystalpharma.com

Cocrystal Pharma, Inc. è una società di biotecnologie che si concentra sulla scoperta e sullo sviluppo di trattamenti terapeutici antivirali per malattie virali gravi e/o croniche. Utilizza tecnologie basate sulla struttura per creare farmaci antivirali destinati principalmente al trattamento del virus dell'epatite C (HCV), del virus dell'influenza, del coronavirus, del norovirus e delle infezioni da virus respiratori. L'azienda sviluppa CC-31244, un inibitore non nucleosidico della polimerasi dell'HCV che ha completato la Fase II di uno studio clinico per il trattamento dell'infezione da HCV, e CC-42344, un inibitore del PB2 che ha completato la Fase I di uno studio clinico per il trattamento dell'infezione da influenza.

Cocrystal Pharma, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Cocrystal Pharma con la sua capitalizzazione di mercato?
COCP statistiche fondamentali
Capitalizzazione di mercato	US$19.23m
Guadagni(TTM)	-US$17.93m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-1.1x

Rapporto P/E

COCP è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
COCP Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$15.72m
Profitto lordo	-US$15.72m
Altre spese	US$2.21m
Guadagni	-US$17.93m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.76
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato COCP nel lungo periodo?

Vedi performance storica e confronto

COCP Panoramica delle azioni

Premi

Analisi del rischio

Cocrystal Pharma, Inc. Concorrenti

NasdaqCM:ACST

US$24.3m

NasdaqCM:VYNE

US$27.7m

NasdaqCM:CARA

US$18.8m

NasdaqGM:TLPH

US$15.3m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Cocrystal Pharma, Inc. Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Advances Cc-42344 in Influenza A Phase 2A Study, Expects Topline Results by Late 2024

Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects

Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates

Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast

Recent updates

Cocrystal Pharma, Inc. Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Advances Cc-42344 in Influenza A Phase 2A Study, Expects Topline Results by Late 2024

Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects

Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates

Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast

Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Announces Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate Cc-42344

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Consensus forecasts updated

Consensus forecasts updated

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Cocrystal Pharma, Inc. Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

Nasdaq Grants 180 Days to Cocrystal Pharma to Regain Compliance

Price target decreased to US$4.08

Cocrystal Pharma, Inc. Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with Cc-42344, a Novel, Broad-Spectrum Influenza A Antiviral

Cocrystal Pharma, Inc., Annual General Meeting, May 18, 2022

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Price target decreased to US$4.08

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Cocrystal Pharma’s Covid-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful in Vitro Potency Against the Sars-Cov-2 Omicron Variant

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.04 loss per share (vs US$0.046 loss in 3Q 2020)

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Cocrystal Pharma, Inc. Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

CocrystalPharma, Inc ’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Co-Founder, Chairman & CEO Gary Wilcox has left the company

Board Member recently sold US$1.7m worth of stock

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Cocrystal Pharma, Inc. Provides Update on its COVID-19 Antiviral Discovery and Development Programs

Cocrystal Pharma updates on COVID-19 antiviral development programs

Price target decreased to US$4.50

Full year 2020 earnings released: US$0.17 loss per share (vs US$1.51 loss in FY 2019)

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Cocrystal Pharma, Inc. Extends Drug Discovery Collaboration with HitGen and InterX, Inc

Board Member notifies of intention to sell stock

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Board Member notifies of intention to sell stock

Cocrystal Pharma Provides Summary of Upcoming Presentation at the Reimagine Health Research Symposium

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck Under Exclusive Worldwide License and Collaboration Agreement

New 90-day high: US$2.19

Cocrystal sees 2021 cash burn of $800k a month

Cocrystal Pharma to test CDI-45205 against coronaviruses

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

New 90-day high: US$1.71

Third quarter 2020 earnings released: US$0.046 loss per share

New 90-day low: US$0.84

Cocrystal Pharma, Inc. Provides Update on Influenza A Program

United States District Court for the District of New Jersey Enters an Order Preliminarily Approving the Stipulation and Agreement of Settlement with Cocrystal Pharma, Inc

New 90-day low - US$0.93